2026 NIAID DMID Omnibus Broad Agency Announcement
AMENDMENT SIX The purpose of Amendment Six is to: Update the “Original Date Offers Due” in the SAM.Gov system to February 21, 2025, 3:00pm EST for Research Area 001. Please note that the “Date Offers ... AMENDMENT SIX The purpose of Amendment Six is to: Update the “Original Date Offers Due” in the SAM.Gov system to February 21, 2025, 3:00pm EST for Research Area 001. Please note that the “Date Offers Due” for Research Area 002 remains unchanged at January 21, 2025, 3:00pm EST. In eCPS, the 2026 Omnibus BAA is separated into four (4) separate solicitations which correspond to each of the two (2) Research Areas, including each of the three (3) Topic numbers for Research Area 001. An Offeror shall ensure that its proposal is submitted to the Research Area and Topic number, if applicable, to which it is applying for in eCPS. Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. ______________________________________________________________________ AMENDMENT FIVE The purpose of Amendment Five is to: Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. ______________________________________________________________________ AMENDMENT FOUR The purpose of Amendment Four is to: Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. ______________________________________________________________________ AMENDMENT THREE The purpose of Amendment Three is to: Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. ____________________________________________________________________________ AMENDMENT TWO The purpose of Amendment Two is to: Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. __________________________________________________________________________ AMENDMENT ONE The purpose of Amendment One is to: Provide NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses. Provide a cut-off date for questions for each Research Area. _________________________________________________________________________ Introduction: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the National Institutes of Health (NIH), an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical countermeasures (MCMs) against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. The following two (2) distinct Research Areas are included in the attached NIAID DMID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2025-1: Research Area 001 – Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for Antimicrobial-Resistant (AMR) Bacterial or Fungal Pathogens For Research Area 001, there are three (3) separate Topics – A, B, and C. Offerors may submit a proposal in response to Topics A, B, and/or C. If proposing to multiple Topics, Offerors must submit separate technical and business proposals for each Topic. Topic A: Therapeutics for AMR Bacterial or Fungal Pathogens The objective of Topic A is to develop new therapeutic products against severe infections and/or drug-resistant strains of the following bacterial and fungal pathogens: a. Pseudomonas aeruginosa, and/or Acinetobacter baumannii; OR b. Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales. For the purpose of this Topic, “therapeutic” activity refers to the cure of disease, by elimination or substantial reduction of infective pathogens, by administration of a pharmaceutical agent after symptoms of disease are clinically observable. An antimicrobial therapeutic candidate refers to an advanced lead series, optimized leads, or product candidate, that is a new chemical entity and either a small molecule (e.g., natural products, nucleosides, or peptides of
Data sourced from SAM.gov.
View Official Posting »